X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs SUN PHARMA - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES SUN PHARMA PIRAMAL ENTERPRISES/
SUN PHARMA
 
P/E (TTM) x 10.5 36.9 28.4% View Chart
P/BV x 1.8 4.1 44.1% View Chart
Dividend Yield % 0.9 0.6 160.9%  

Financials

 PIRAMAL ENTERPRISES   SUN PHARMA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-18
SUN PHARMA
Mar-17
PIRAMAL ENTERPRISES/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs3,083842 366.1%   
Low Rs1,902572 332.3%   
Sales per share (Unadj.) Rs589.7131.6 448.1%  
Earnings per share (Unadj.) Rs284.032.7 868.5%  
Cash flow per share (Unadj.) Rs310.538.0 817.7%  
Dividends per share (Unadj.) Rs25.003.50 714.3%  
Dividend yield (eoy) %1.00.5 202.7%  
Book value per share (Unadj.) Rs1,467.0152.7 960.6%  
Shares outstanding (eoy) m180.272,399.26 7.5%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x4.25.4 78.7%   
Avg P/E ratio x8.821.6 40.6%  
P/CF ratio (eoy) x8.018.6 43.1%  
Price / Book Value ratio x1.74.6 36.7%  
Dividend payout %8.810.7 82.2%   
Avg Mkt Cap Rs m449,3321,696,877 26.5%   
No. of employees `0006.817.5 39.1%   
Total wages/salary Rs m19,88149,023 40.6%   
Avg. sales/employee Rs Th15,535.618,028.3 86.2%   
Avg. wages/employee Rs Th2,905.42,798.8 103.8%   
Avg. net profit/employee Rs Th7,482.54,479.5 167.0%   
INCOME DATA
Net Sales Rs m106,310315,784 33.7%  
Other income Rs m2,5956,232 41.6%   
Total revenues Rs m108,906322,016 33.8%   
Gross profit Rs m51,599100,893 51.1%  
Depreciation Rs m4,77312,648 37.7%   
Interest Rs m29,7833,998 744.9%   
Profit before tax Rs m19,63890,479 21.7%   
Minority Interest Rs m2,8010-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-28,76412,116 -237.4%   
Profit after tax Rs m51,20378,462 65.3%  
Gross profit margin %48.531.9 151.9%  
Effective tax rate %-146.513.4 -1,093.9%   
Net profit margin %48.224.8 193.8%  
BALANCE SHEET DATA
Current assets Rs m118,154329,537 35.9%   
Current liabilities Rs m462,260178,870 258.4%   
Net working cap to sales %-323.747.7 -678.4%  
Current ratio x0.31.8 13.9%  
Inventory Days Days2779 33.6%  
Debtors Days Days4783 55.9%  
Net fixed assets Rs m113,727204,766 55.5%   
Share capital Rs m3612,399 15.0%   
"Free" reserves Rs m264,093363,997 72.6%   
Net worth Rs m264,454366,397 72.2%   
Long term debt Rs m242,20614,361 1,686.6%   
Total assets Rs m726,834614,102 118.4%  
Interest coverage x1.723.6 7.0%   
Debt to equity ratio x0.90 2,336.7%  
Sales to assets ratio x0.10.5 28.4%   
Return on assets %11.113.4 83.0%  
Return on equity %19.421.4 90.4%  
Return on capital %10.324.8 41.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,11044,118 34.2%   
Fx outflow Rs m4,29824,484 17.6%   
Net fx Rs m10,81319,634 55.1%   
CASH FLOW
From Operations Rs m-159,66670,822 -225.4%  
From Investments Rs m-17,677-42,216 41.9%  
From Financial Activity Rs m186,503-22,854 -816.1%  
Net Cashflow Rs m9,3646,107 153.3%  

Share Holding

Indian Promoters % 52.9 63.7 83.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 5.1 78.0%  
FIIs % 26.6 23.0 115.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 8.3 198.8%  
Shareholders   93,274 133,026 70.1%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  ELDER PHARMA  NOVARTIS  DR. DATSONS LABS  

Compare PIRAMAL ENTERPRISES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Nifty Hits Fresh Record High; Sensex Up Over 330 Points(12:30 pm)

After opening the day on a positive note, stock markets in India continued their momentum and went on to scale their record-high levels.

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY19); Net Profit Down 152.5% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 1 bn (down 152.5% YoY). Sales on the other hand came in at Rs 29 bn (up 28.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Aug 20, 2018 02:11 PM

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES - IPCA LABS COMPARISON

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS